• SPX
  • $5,969.34
  • 0.35 %
  • $20.63
  • DJI
  • $44,296.51
  • 0.97 %
  • $426.16
  • N225
  • $38,283.85
  • 0.68 %
  • $257.68
  • FTSE
  • $8,262.08
  • 1.38 %
  • $112.81
  • IXIC
  • $19,003.65
  • 0.16 %
  • $31.23
Mirum Pharmaceuticals, Inc. (MIRM) Stock Price, News & Analysis

Mirum Pharmaceuticals, Inc. (MIRM) Stock Price, News & Analysis

Currency in USD Disclaimer

$44.70

$1.22

(2.79%)

Day's range
$43.3
Day's range
$44.9
50-day range
$36.86
Day's range
$48.89
  • Country: US
  • ISIN: US6047491013
52 wk range
$23.14
Day's range
$48.89


We are preparing, please wait

Analyst Ratings

Key Stats

Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.

Stock Score/grades

The Stock Score/Grades evaluate bankruptcy risk and assess the financial strength and fundamental health of a company

  • Altman Z Score 2.11
  • Piotroski Score 2.00
  • Grade Buy
  • Symbol (MIRM)
  • Company Mirum Pharmaceuticals, Inc.
  • Price $44.70
  • Changes Percentage (2.79%)
  • Change $1.22
  • Day Low $43.30
  • Day High $44.90
  • Year High $48.89

Mirum Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases. The company's lead product candidate is LIVMARLI, an investigational oral drug for the treatment of progressive familial intrahepatic cholestasis disease, as well as for the treatment of Alagille syndrome and biliary atresia disease. It also develops Volixibat drug for treatment of intrahepatic cholestasis of pregnancy and primary sclerosing cholangitis. Mirum Pharmaceuticals, Inc. was incorporated in 2018 and is headquartered in Foster City, California.

  • Last Earnings
  • Ex-Dividend for 5/16 Dividend
  • Dividend Payable
  • Today N/A
  • Next Earnings (Estimated) 02/26/2025
  • Fiscal Year End N/A

  • Average Stock Price Target $59.50
  • High Stock Price Target $75.00
  • Low Stock Price Target $39.00
  • Potential Upside/Downside N/A
  • Consensus Rating Strong Sell
  • Rating Score (0-4) N/A
  • Research Coverage N/A

  • EPS (Most Recent Fiscal Year) -$3.74
  • Trailing P/E Ratio -6.7
  • Forward P/E Ratio -6.7
  • P/E Growth -6.7
  • Net Income $-163,415,000

Income Statement

Quarterly

Annual

Latest News of MIRM

The Latest News section aggregates recent news posts from various news outlets, offering a comprehensive overview of the most recent developments related to the topic.

Enter your phone number to get Breaking News Updates

Stay ahead with instant updates! Enter your phone number for breaking news alerts, ensuring you're always in the know with the latest developments.


We are preparing, please wait

Mirum Pharmaceuticals, Inc. Frequently Asked Questions

  • What were the earnings of MIRM in the last quarter?

    In the last quarter Mirum Pharmaceuticals, Inc. earnings were on Tuesday, November, 12th. The Mirum Pharmaceuticals, Inc. maker reported -$0.30 EPS for the quarter, beating analysts' consensus estimates of -$0.45 by $0.15.

  • What is the Mirum Pharmaceuticals, Inc. stock price today?

    Today's price of Mirum Pharmaceuticals, Inc. is $44.70 — it has increased by +2.79% in the past 24 hours. Watch Mirum Pharmaceuticals, Inc. stock price performance more closely on the chart.

  • Does Mirum Pharmaceuticals, Inc. release reports?

    Yes, you can track Mirum Pharmaceuticals, Inc.'s financials in yearly and quarterly reports directly on Stocks.News.

  • What is the Mirum Pharmaceuticals, Inc. stock forecast?

    Watch the Mirum Pharmaceuticals, Inc. chart and read a more detailed Mirum Pharmaceuticals, Inc. stock forecast to see what analysts suggest you do with its shares.

  • What is Mirum Pharmaceuticals, Inc. stock ticker?

    The stock ticker can vary on the respective exchange. For instance, on NASDAQ, exchange stock trades by Mirum Pharmaceuticals, Inc. stock ticker.

  • How to buy Mirum Pharmaceuticals, Inc. stocks?

    Like other stocks, MIRM shares are sold on stock exchanges such as NASDAQ. The best way to obtain them is through an online stock broker. Open an account, follow the broker's steps, and start trading.

  • What is Mirum Pharmaceuticals, Inc.'s EBITDA?

    Mirum Pharmaceuticals, Inc. measures a company's operating performance, and its growth indicates efficiency improvements. Access more stats in Mirum Pharmaceuticals, Inc.’s financial statements.

  • What is the Mirum Pharmaceuticals, Inc.'s net income ratio for the financial year 2023?

    The net income ratio for the financial year 2023 is -0.8768122163, which equates to approximately -87.68%. This ratio indicates the percentage of net income generated from total revenue and serves as a key measure of a company’s profitability.

  • Should I invest in Mirum Pharmaceuticals, Inc. stocks?

    Investing in stocks requires thorough research. Carefully examine all available data, including Mirum Pharmaceuticals, Inc.'s financials relevant news, and technical analysis. Mirum Pharmaceuticals, Inc.'s technical analysis shows a “buy” rating today and a one-week “buy” rating. Since market conditions can change, it’s wise to look at longer-term trends — the one-month rating for Mirum Pharmaceuticals, Inc. stock currently indicates a “sell” signal. For more insights, review Mirum Pharmaceuticals, Inc.’s technical analysis.

  • A revenue figure for Mirum Pharmaceuticals, Inc. for its last quarter?

    Mirum Pharmaceuticals, Inc. published it's last quarterly revenues at $90.38 M.

Portfolio Sync Solutions

Streamline your investment strategy with our portfolio synchronization tools. Seamlessly manage and track your holdings across platforms for enhanced

GET STARTED
Portfolio Sync Solutions
×
New Alert

Select an alert type

Choose sentiment spike or mentions spike or both to receive email alerts and app notification for the selected stock.
Note: Please be aware that you will receive an email only once a day, around 8:00 AM (EST), in the event of any spike.
In future if you don't want to receive any email then delete stocks added into alert section.

New Alert

Setup alert

×

Premium Content

This content is only available for premium members. Please become a paid member to access.

Download App

Currently, memberships can only be purchased through the app.

×

Log In


or

download app using google store Continue with Google download app using apple Continue with Apple

Email Verification

An email with a verification code has been sent to your email address.

Welcome to Stocks.News!

Create Your Account

Email Verification

An email with a verification code has been sent to your email address.